dr. michelle fanale on frontline brentuximab in subtypes of lymphoma
Published 11 years ago • 719 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:33
dr. fanale on brentuximab vedotin as frontline treatment for lymphoma
-
2:27
dr. fanale discusses brentuximab vedotin in cd30-positive lymphomas
-
2:43
hodgkin lymphoma: using brentuximab vedotin frontline
-
1:25
dr. fanale on challenges facing treatments in t-cell lymphoma
-
0:57
dr. flinn on fda approval of frontline brentuximab vedotin with avd in hodgkin lymphoma
-
0:58
dr. michelle fanale on the potential of antibody-drug conjugates
-
6:13
brentuximab vedotin
-
1:15
dr. advani discusses cd30 as a target and brentuximab vedotin in alcl
-
10:09
understanding diffuse large b-cell lymphoma with jennifer amengual, md
-
12:13
understanding follicular lymphoma
-
13:46
understanding follicular lymphoma with sarah rutherford, md
-
1:50
dr. fanale on clinical trials for t-cell lymphoma
-
1:25
dr. brammer on brentuximab vedotin for patients with t-cell lymphoma
-
1:27
patient selection for newly approved agents in t-cell lymphoma
-
4:07
utilization of brentuximab vedotin in hodgkin lymphoma
-
1:03
relevance: rituximab and lenalidomide in fl
-
0:44
dr. hamlin on brentuximab vedotin pharmacology
-
1:01
ask unmc: lymphoma treatments
-
0:46
alcanza: brentuximab vedotin improves orr and pfs in ctcl
-
1:47
dr. hamlin discusses integrating brentuximab vedotin
-
1:22
dr. cohen on the evolution of antibodies in lymphoma
-
1:52
dr. diehl discusses brentuximab vedotin